| Literature DB >> 31635328 |
Kristin M Klohonatz1, Stephen J Coleman2, Ashley D Cameron3, Ann M Hess4, Kailee J Reed5, Angela Canovas6, Juan F Medrano7, Alma D Islas-Trejo8, Ted Kalbfleisch9, Gerrit J Bouma10, Jason E Bruemmer11,12.
Abstract
Maternal recognition of pregnancy (MRP) in the mare is not well defined. In a non-pregnant mare, prostaglandin F2α (PGF) is released on day 14 post-ovulation (PO) to cause luteal regression, resulting in loss of progesterone production. Equine MRP occurs prior to day 14 to halt PGF production. Studies have failed to identify a gene candidate for MRP, so attention has turned to small, non-coding RNAs. The objective of this study was to evaluate small RNA (<200 nucleotides) content in endometrium during MRP. Mares were used in a cross-over design with each having a pregnant and non-mated cycle. Each mare was randomly assigned to collection day 11 or 13 PO (n = 3/day) and endometrial biopsies were obtained. Total RNA was isolated and sequencing libraries were prepared using a small RNA library preparation kit and sequenced on a HiSeq 2000. EquCab3 was used as the reference genome and DESeq2 was used for statistical analysis. On day 11, 419 ncRNAs, representing miRNA, snRNA, snoRNA, scaRNA, and vaultRNA, were different between pregnancy statuses, but none on day 13. Equine endometrial ncRNAs with unknown structure and function were also identified. This study is the first to describe ncRNA transcriptome in equine endometrium. Identifying targets of these ncRNAs could lead to determining MRP.Entities:
Keywords: embryo; endometrium; equine; maternal recognition of pregnancy; non-coding RNA; pregnancy
Mesh:
Substances:
Year: 2019 PMID: 31635328 PMCID: PMC6826835 DOI: 10.3390/genes10100821
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
Figure 1Distribution of differentially expressed families of ncRNA in endometrial samples on day 11 from both pregnant and non-pregnant mares. This figure represents the families of ncRNA differentially expressed (p ≤ 0.05) in endometrial samples on day 11.
Top 20 differentially expressed non-coding RNA in the endometrium on day 11 with known structure.
| Feature ID | ncRNA Name | ncRNA Description | Day 11P+ Average | Day 11NP Average | Day 11 |
|---|---|---|---|---|---|
|
| U109 | snoRNA | 1 | 71,765 | 2.1E-07 |
|
| U1 | snRNA | 0 | 21,351 | 5.4E-07 |
|
| eca-mir-9109 | miRNA | 9 | 15,762 | 6.3E-07 |
| ENSECAT00000055936 | eca-mir-8986b | miRNA | 448 | 0 | 1.1E-06 |
|
| eca-mir-323 | miRNA | 11 | 39,904 | 1.2E-06 |
|
| SNORA69 | snoRNA | 49 | 36,277 | 6.7E-06 |
|
| MIR15B | miRNA | 81 | 39,222 | 9.2E-06 |
|
| U6 | snRNA | 0 | 4866 | 1.5E-05 |
|
| MIR137 | miRNA | 2 | 2916 | 1.6E-05 |
|
| SNORA2B | snoRNA | 4 | 5177 | 1.7E-05 |
|
| SNORD65 | snoRNA | 20 | 9278 | 1.7E-05 |
|
| SCARNA17 | scaRNA | 16 | 5915 | 2.3E-05 |
|
| eca-mir-9080 | miRNA | 13 | 5718 | 4.4E-05 |
|
| SNORA71 | snoRNA | 22 | 8449 | 4.4E-05 |
|
| eca-mir-652 | miRNA | 24 | 9678 | 4.4E-05 |
|
| SNORA12 | snoRNA | 2 | 1924 | 4.6E-05 |
|
| MIR1306 | miRNA | 15 | 4741 | 5.1E-05 |
|
| eca-mir-582 | miRNA | 3 | 2342 | 1.0E-04 |
|
| SNORA36A | snoRNA | 48 | 12,262 | 1.3E-04 |
|
| SNORD59A | snoRNA | 246 | 38,612 | 1.8E-04 |
This table breaks down the significant (p ≤ 0.05) ncRNA with known structure and function in the endometrium on day 11 ranked based upon significance. The average represents the average number of reads determined during Salmon analysis. Non-coding RNA names bolded indicate they were more highly expressed in samples from pregnant mares.
Twenty most significant KEGG Pathways.
| KEGG Pathway | |
|---|---|
| Protein processing in endoplasmic reticulum | 1.54E-12 |
| Proteoglycans in cancer | 3.66E-12 |
| Adherens junction | 1.97E-11 |
| Viral carcinogenesis | 1.97E-11 |
| Hippo signaling pathway | 2.06E-08 |
| p53 signaling pathway | 3.44E-07 |
| Cell cycle | 3.74E-07 |
| Renal cell carcinoma | 4.62E-07 |
| Pancreatic cancer | 1.06E-06 |
| Ubiquitin mediated proteolysis | 1.54E-06 |
| Neurotrophin signaling pathway | 1.54E-06 |
| TGF-beta signaling pathway | 2.25E-06 |
| Prostate cancer | 2.25E-06 |
| Epstein–Barr virus infection | 2.25E-06 |
| Pathways in cancer | 2.25E-06 |
| Glioma | 2.77E-06 |
| mRNA surveillance pathway | 4.95E-06 |
| Chronic myeloid leukemia | 5.02E-06 |
| Hepatitis B | 5.02E-06 |
| Endocytosis | 6.27E-06 |